45 studies found for:    Open Studies | "Neurofibromatosis 1"
Show Display Options
Rank Status Study
21 Recruiting Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
Conditions: Neurofibromatosis;   MPNST
Interventions: Procedure: MRI, FDG-PET/CT scans;   Procedure: [18F]-FLT-PET/CT scans
22 Recruiting Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1.
Condition: Neurofibromatosis Type 1
23 Not yet recruiting Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)
Condition: Neurofibromatosis Type 1 (NF1)
Intervention: Drug: Cholecalciferol
24 Not yet recruiting Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibroma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Selumetinib
25 Recruiting Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibromas
Intervention: Other: Acceptance and Commitment Therapy (ACT)
26 Recruiting Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Conditions: Neurofibromatosis Type 2;   Neuroma, Acoustic
Intervention: Drug: RAD001, everolimus
27 Recruiting Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas
Conditions: Neurofibromatosis Type 2;   Progressive Vestibular Schwannomas
Intervention: Drug: Bevacizumab
28 Recruiting Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF
Condition: Neurofibromatosis
Intervention: Other: Questionnaires
29 Recruiting Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)
Condition: Neurofibromatoses
Interventions: Drug: Levulan (5-aminolevulinic acid) uptake.;   Drug: Levulan (5-aminolevulinic acid) photodynamic therapy.
30 Available Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
Conditions: Neurofibromatosis Type 2;   Severe Profound Sensorineural Hearing Loss
Intervention: Device: Nucleus Profile ABI541 Auditory Brainstem Implant
31 Recruiting Feasibility and Clinically Application of Magnetic Resonance Fingerprinting
Conditions: Neurofibromatosis Type 1;   Brain Tumor;   Glioma
Interventions: Device: Magnetic Resonance Imaging;   Device: Magnetic Resonance Fingerprinting
32 Unknown  Concentration and Activity of Lapatinib in Vestibular Schwannomas
Conditions: Vestibular Schwannoma;   NF2;   Neurofibromatosis 2;   Acoustic Neuroma;   Auditory Tumor
Intervention: Drug: lapatinib
33 Recruiting Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Conditions: Vestibular Schwannoma;   Meningioma;   Acoustic Neuroma;   Neurofibromatosis Type 2
Intervention: Drug: AR-42
34 Recruiting Effect of Implant Position on Magnetic Resonance Image Distortion
Condition: Neurofibromatosis Type 2
Intervention: Device: MR imaging
35 Recruiting Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
Conditions: Neurofibromatosis Type 2;   Vestibular Schwannomas;   Meningiomas
Intervention: Drug: RAD001
36 Recruiting Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
Conditions: Neurofibromatosis Type 1;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
Interventions: Drug: Lenalidomide;   Other: Pharmacological Study
37 Recruiting Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Conditions: Glioma;   Neurofibromatosis Type 1;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Selumetinib
38 Recruiting Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
Condition: Plexiform Neurofibromas
Intervention: Drug: Imatinib Mesylate
39 Recruiting PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Conditions: Neurofibroma, Plexiform;   Precursor Cell Lymphoblastic Leukemia-Lymphoma;   Leukemia, Prolymphocytic, Acute;   Sarcoma
Intervention: Drug: PLX3397
40 Recruiting Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS
Condition: Benign Prostatic Hyperplasia
Interventions: Drug: Tamsulosin HCL 0.4mg;   Drug: Tamsulosin HCL 0.2mg

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-45) Show next page of results    Last Page
Indicates status has not been verified in more than two years